In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

The article " 3 Biopharmaceutical Stocks Bucking the Sell-Off " first appeared on MarketBeat.

Cartesian Therapeutics Inc. unveiled 12-month efficacy and safety data from the phase IIb trial of Descartes-08 in participants with generalized myasthenia gravis (MG). Participants dosed with a ...

FacebookTweetPin It was only yesterday that BlackRock CEO Larry Fink said that “we’re probably in a recession” right now.

KalVista has licenced the commercialisation rights for sebetralstat, a hereditary angioedema (HAE) treatment, to Kaken in ...

Shares of KalVista Pharmaceuticals (NASDAQ:KALV) spiked in the premarket on Tuesday after the company disclosed a licensing ...

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the proposed merger of the companies.

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Wall Street on Friday suffered its biggest weekly retreat since the peak of the COVID-19 pandemic collapse in 2020. The panic ...

Potential Alumis Inc. (NASDAQ:ALMS) shareholders may wish to note that the Independent Director, Alan Colowick, recently bought US$130k worth of stock, paying US$7.04 for each share. Although the ...